Literature DB >> 10404957

Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions.

M Ohishi1, M Ueda, H Rakugi, T Naruko, A Kojima, A Okamura, J Higaki, T Ogihara.   

Abstract

BACKGROUND: Studies using cell cultures and animal models have indicated an important role for angiotensin II in atherosclerosis. In humans, at least two major enzymes are involved in the conversion of angiotensin I to angiotensin II: so-called angiotensin-converting enzyme (ACE) and chymase. Enhanced activation of chymase in atherosclerotic tissue homogenates has been reported in animal models, but its contribution to the generation of angiotensin II has not been studied.
OBJECTIVE: To clarify the localization of chymase and its pathophysiologic role in the formation of angiotensin II, using human coronary arteries. DESIGN AND METHODS: Twenty-four coronary artery segments obtained from 14 autopsied patients were characterized histologically into the following categories: normal coronary arteries with diffuse intimal thickening, hypercellular lesions, atheromatous plaques and fibrosclerotic plaques. We compared the cellular localization of chymase, ACE and angiotensin II expression using immunocytochemical techniques.
RESULTS: Chymase was expressed only in the cytosole of mast cells in all segments. On the basis of the histologic study, the number of chymase-positive cells in the intima of atheromatous plaques was significantly higher than that in normal coronary arteries with diffuse intimal thickening. The expression of angiotensin II in the intima was enhanced in hypercellular lesions and atheromatous plaques. Localization of angiotensin II in the intima was associated with that of ACE. Immunodouble staining did not show colocalization of angiotensin II and chymase.
CONCLUSIONS: These results suggest an important role for the production of angiotensin II by ACE in the progression of atherosclerosis in human coronary arteries. Enhanced expression of chymase appears not to be involved in angiotensin II production in the intima.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404957     DOI: 10.1097/00004872-199917040-00013

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion.

Authors:  Tadashi Suehiro; Tatsuhito Morita; Mari Inoue; Yoshitaka Kumon; Yukio Ikeda; Kozo Hashimoto
Journal:  Hum Genet       Date:  2004-05-26       Impact factor: 4.132

2.  Phenotypic change and accumulation of smooth muscle cells in strictures in Crohn's disease: relevance to local angiotensin II system.

Authors:  Takehisa Suekane; Yoshihiro Ikura; Kenji Watanabe; Junko Arimoto; Yoko Iwasa; Yoshimi Sugama; Soichiro Kayo; Kenichi Sugioka; Takahiko Naruko; Kiyoshi Maeda; Kosei Hirakawa; Tetsuo Arakawa; Makiko Ueda
Journal:  J Gastroenterol       Date:  2010-04-02       Impact factor: 7.527

3.  Increased expression and co-localization of ACE, angiotensin II AT(1) receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries.

Authors:  Mitsuru Ohishi; Gregory J Dusting; Paul A Fennessy; Frederick Ao Mendelsohn; Xiao C Li; Jia L Zhuo
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-04-30

4.  Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries.

Authors:  Takeo Itoh; Junko Kajikuri; Toyohiro Tada; Yoshikatsu Suzuki; Yoshio Mabuchi
Journal:  J Physiol       Date:  2003-03-21       Impact factor: 5.182

5.  How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial.

Authors:  Vernon VS Bonarjee; Kenneth Dickstein
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

Review 6.  Clinical trial update: focus on the ONTARGET study.

Authors:  David Fitchett
Journal:  Vasc Health Risk Manag       Date:  2007
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.